Ameliorative effect of purple bamboo salt-pharmaceutical acupuncture on cisplatin-induced ototoxicity.
CONCLUSIONS
Our findings demonstrated that purple bamboo salt (PBS)-pharmaceutical acupuncture has an ameliorative effect on cisplatin-induced ototoxicity.


OBJECTIVE
We have previously reported that PBS exhibited anti-allergic and anti-inflammatory actions in vitro and in vivo. Pharmaceutical acupuncture is a traditional oriental therapeutic technique that combines acupuncture with herbal treatment. The aim of this study was to investigate the protective effect and mechanism of PBS-pharmaceutical acupuncture against cisplatin-induced ototoxicity in the auditory cell line, HEI-OC1, and in vivo.


METHODS
The ELISA method, a caspase-3 assay, an MTT assay, Western blot analysis, and a luciferase assay were utilized to investigate the effect of PBS in vivo and in vitro.


RESULTS
When it was acupunctured at the Ermen acupoint (triple energizer meridian 21) after an administration of cisplatin, PBS-pharmaceutical acupuncture significantly suppressed interleukin (IL)-6 production and caspase-3 activation induced by cisplatin in the cochlea. In addition, PBS significantly inhibited cisplatin-induced apoptosis and IL-6 production in HEI-OC1 cells. PBS also suppressed cytochrome c release and caspase-3 activation, and it inhibited extracellular signal-related kinase and nuclear factor-κB activation in HEI-OC1 cells.
Myung
Noh-Yil
NY
Acupuncture and Meridian Science Research Center, Kyung Hee University, Republic of Korea.
Choi
In-Hwa
IH
Jeong
Hyun-Ja
HJ
Kim
Hyung-Min
HM
D015669:Acupuncture Points; D020831:Acupuncture, Ear / Q000379:methods*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002460:Cell Line; D002945:Cisplatin / Q000633:toxicity*; D045304:Cytochromes c / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors; D018072:Hair Cells, Auditory, Outer / Q000187:drug effects*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000276:immunology; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D055670:Medicine, Korean Traditional; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D008517:Phytotherapy / Q000379:methods*; D010936:Plant Extracts / Q000494:pharmacology*; D011208:Powders; D031787:Sasa
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D016207:Cytokines; D015850:Interleukin-6; D016328:NF-kappa B; D010936:Plant Extracts; D011208:Powders; D045304:Cytochromes c; D048049:Extracellular Signal-Regulated MAP Kinases; D053148:Caspase 3; D002945:Cisplatin